Zacks.com on MSN3 小时
Gilead, MRK Report Data From Investigational Combination Study for HIV
Gilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational ...
Future Market Insights8 小时
Human Immunodeficiency Virus Type 1 (HIV 1) Market is predicted to be valued US$ 62.37 ...
The 1) Market is expected to reach a substantial USD 34.83 billion by 2033, according to a new report. This reflects a ...
pharmaphorum11 小时
Gilead, MSD say HIV combo could be weekly, oral HIV drug
Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...
The Pharma Letter21 小时
Gilead and Merck tout first weekly oral HIV treatment
US drugmakers Gilead Sciences (Nasdaq: GILD) and Merck & Co (NYSE: MRK) have announced new results from a Phase II clinical ...
来自MSN1 天
Gilead, Merck announce from Phase 2 islatravir/lenacapavir combo study
Gilead Sciences (GILD) and Merck (MRK) announced new results from a Phase 2 clinical study evaluating the investigational ...
Gilead And Merck Report Phase 2 Results For Islatravir And Lenacapavir Combination In HIV ...
Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...
Business Wire1 天
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational ...
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...